Cited by 686Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

André, Thierry, de Gramont, Armand, Vernerey, Dewi, Chibaudel, Benoist, Bonnetain, Franck, Tijeras-Raballand, Annemilaï, Scriva, Aurelie, Hickish, Tamas, Tabernero, Josep, Van Laethem, Jean Luc, Banzi, Maria, Maartense, Eduard, Shmueli, Einat, Carlsson, Goran U., Scheithauer, Werner, Papamichael, Demetris, Möehler, Marcus, Landolfi, Stefania, Demetter, Pieter, Colote, Soudhir, Tournigand, Christophe, Louvet, Christophe, Duval, Alex, Fléjou, Jean-François, de Gramont, Aimery·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2015.63.4238

Open this paper in CoChat — free account

Abstract

Purpose: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods: Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results: After a median follow-up of 9.5 years, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (hazard ratio [HR], 0.85; P = .043) in the whole population, 79.5% versus 78.4% for stage II (HR, 1.00; P = .980), and 59.0% versus 67.1% for stage III (HR, 0.80; P = .016) disease. Ninety-five patients (9.4%) had MMR-deficient (dMMR) tumors, and 94 (10.4%) had BRAF mutation. BRAF mutation was not prognostic for OS (P = .965), but dMMR was an independent prognostic factor (HR, 2.02; 95% CI, 1.15 to 3.55; P = .014). HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95% CI, 0.20 to 1.12) and 0.41 (95% CI, 0.16 to 1.07), respectively, in patients with stage II to III dMMR and 0.50 (95% CI, 0.25 to 1.00) and 0.66 (95% CI, 0.31 to 1.42), respectively, in those with BRAF mutation. Conclusion: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.4238

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Self-citation
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J. A., McAllister, P. K., Cutsem, E. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,438
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A. M. R., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,436
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,178
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
Kuebler, J. P., Wieand, H. S., O’Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P. N., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,055

Show all 32 references

Sorted by citations

Items 301–400 of 686

Hospital Variability in Use of Adjuvant Chemotherapy for Patients with Stage 2 and 3 Colon Cancer
Daly, M. C., Hanseman, D. J., Abbott, D. E., Shah, S. A., & Paquette, I. M. (2016) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000704 · Cited by 11
Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer
Huang, X., Li, F., Wang, L., Xiao, M., Ni, L., Jiang, S., Ji, Y., Zhang, C., Zhang, W., Wang, J., et al. (2020) · Endoscopy · doi:10.1055/a-1157-8611 · Cited by 11
Systemic Sentinel Lymph Node Detection Using Fluorescence Imaging After Indocyanine Green Intravenous Injection in Colorectal Cancer: Protocol for a Feasibility Study
Liberale, G., Vankerckhove, S., Bouazza, F., Galdón, M. G., Larsimont, D., Moreau, M., Bourgeois, P., & Donckier, V. (2020) · JMIR Research Protocols · doi:10.2196/17976 · Cited by 11
Adjuvant Treatment with 5-Fluorouracil and Oxaliplatin Does Not Influence Cardiac Function, Neurovascular Control, and Physical Capacity in Patients with Colon Cancer
Groehs, R. V., Negrao, M. V., Hajjar, L. A., Jordão, C. P., de Carvalho, B. Z. O., Toschi‐Dias, E., Andrade, A., Hodas, F. P., Alves, M. J. D. N. N., de Oliveira, A. S., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0225 · Cited by 11
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
Knapen, D. G., Cherny, N. I., Zygoura, P., Latino, N. J., Douillard, J.-Y., Dafni, U. G., de Vries, E. G. E., & de Groot, D. J. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000681 · Cited by 10
POLE mutations in colorectal cancer: a new biomarker?
Eng, C. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30030-9 · Cited by 12
Microsatellite instability in Costa Rican patients with colorectal adenocarcinoma and its association with overall survival and response to fluoropyrimidine-based chemotherapy
Ramos-Esquivel, A., Rodriguez-Porras, L., & Juan, P. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101680 · Cited by 11
Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment
Boccaccino, A., Cassaniti, M., Rossini, D., Faccani, L., Casadio, C., & Tamberi, S. (2025) · Cancers · doi:10.3390/cancers17203336 · Cited by 10
Optimizing Adjuvant Therapy and Survivorship Care of Stage III Colon Cancer
Loree, J. M., & Cheung, W. Y. (2016) · Future Oncology · doi:10.2217/fon-2016-0109 · Cited by 10
Colorectal Cancer
Lawler, M., Johnston, B., Schaeybroeck, S. V., Salto‐Tellez, M., Wilson, R. H., Dunlop, M. G., & Johnston, P. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00074-8 · Cited by 10
Neoantigens and their clinical applications in human gastrointestinal cancers
Eshkiki, Z. S., Agah, S., Tabaeian, S. P., Sedaghat, M., Dana, F., Talebi, A., & Akbari, A. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02776-y · Cited by 10
Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer
Yeh, Y., Tsai, H., Chen, P.-J., Chen, Y., Su, W., Chang, T., Huang, C., & Wang, J. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2188195 · Cited by 10
Circulating Tumor DNA: Clinical Monitoring and Early Detection
Corcoran, R. B. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055719 · Cited by 10
Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer
Shaib, W. L., Zakka, K., Jiang, R., Yan, M., Alese, O. B., Akce, M., Wu, C. S.-Y., Behera, M., & El‐Rayes, B. F. (2020) · Cancer · doi:10.1002/cncr.33049 · Cited by 10
Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
Zhou, M., Thompson, T., Lin, H., Chen, V. W., Karlitz, J. J., Fontham, E. T. H., Theall, K. P., Zhang, L., Hsieh, M., Pollack, L. A., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.09.008 · Cited by 10
Development and external validation of a novel nomogram for screening Chinese Lynch syndrome: based on a multicenter, population study
Yang, M., Li, D., Wu, J., Zhu, L., Ju, H., Sun, Y. K., Shan, Y., Yang, C., Dong, J., Wang, L., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211023290 · Cited by 10
A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification—Defining novel predictive and prognostic markers in stage III colon cancer
Margalit, O., Mamtani, R., Yang, Y., Reiss, K. A., Golan, T., Halpern, N., Aderka, D., Giantonio, B. J., Shacham‐Shmueli, E., & Boursi, B. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.022 · Cited by 10
Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
Zheng, E., Włodarczyk, M., Węgiel, A., Osielczak, A., Możdżan, M., Biskup, L., Grochowska, A., Wołyniak, M., Gajewski, D., Porc, M., et al. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1398289 · Cited by 10
Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer
Xu, C., Xia, P., Li, J., Lewis, K. B., Ciombor, K. K., Wang, L., Smith, J. J., Beauchamp, R. D., & Chen, X. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101661 · Cited by 11
ABALON regulates mitophagy and 5-FU sensitivity in colorectal cancer via PINK1-Parkin pathway
Liu, H., Huang, Y. K., Zhao, C., Wang, G., & Wang, X. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-933 · Cited by 9
Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Baron, E., Sardi, A., King, M. C., Nikiforchin, A., Lopez‐Ramirez, F., Nieroda, C. A., Gushchin, V., & Ledakis, P. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.08.022 · Cited by 9
Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI
Volovăț, S. R., Augustin, I. G., Zob, D., Boboc, D., Amurariti, F., Volovat, C. D., Ştefănescu, C., Stolniceanu, C. R., Ciocoiu, M., Dumitras, E. A., et al. (2022) · Cancers · doi:10.3390/cancers14194834 · Cited by 10
PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance
Parisi, E., Hidalgo, I., Montal, R., Pallisé, O., Tarragona, J., Sorolla, A., Novell, A., Campbell, K., Sorolla, M. A., Casali, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310889 · Cited by 8
A national evaluation of adjuvant chemotherapy in pT4N0M0 colon cancer from the National Cancer Database
de Paula, T. R., & Keller, D. S. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad164 · Cited by 9
The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed
Hernando-Cubero, J., Matos, I. G., Alonso-Orduña, V., & Capdevila, J. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-017-9946-5 · Cited by 9
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
Jongeneel, G., Greuter, M. J. E., van Erning, F. N., Koopman, M., Medema, J. P., Kandimalla, R., Goel, A., Bujanda, L., Meijer, G. A., Fijneman, R. J. A., et al. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01199-4 · Cited by 9
Personalized Adjuvant Treatment of Colon Cancer
Taghizadeh, H., & Prager, G. W. (2020) · Visceral Medicine · doi:10.1159/000508175 · Cited by 10
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
Hu, H., Wu, Z., Wang, C., Huang, Y. J., Zhang, J., Cai, Y., Xie, X., Li, J., Shen, C., Li, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.579478 · Cited by 9
The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study
Takeshita, E., Ishibashi, K., Koda, K., Oda, N., Yoshimatsu, K., Sato, Y., Oya, M., Yamaguchi, S., Nakajima, H., Momma, T., et al. (2021) · Surgery Today · doi:10.1007/s00595-021-02230-8 · Cited by 10
Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival
Piredda, M. L., Ammendola, S., Sciammarella, C., Turri, G., Bagante, F., Fassan, M., Mafficini, A., Mombello, A., Cataldi, S., Paolino, G., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153519 · Cited by 9
Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis
Huang, W., Hsu, H., Chang, S., Chou, W., Chang, P., Chiang, S.-F., Chang, J. W., Chen, J., Yang, T., & See, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.693009 · Cited by 10
Predictive risk-score model for selection of patients with high-risk stage II colon cancer for adjuvant systemic therapy
Straker, R. J., Heo, D. H., Shannon, A. B., Fraker, D. L., Shanmugan, S., Schneider, C. J., Mahmoud, N. N., Miura, J. T., & Karakousis, G. C. (2021) · Surgery · doi:10.1016/j.surg.2021.10.066 · Cited by 9
Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis
Song, J. H., Lee, J. H., Kim, S. H., & Um, J. W. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04096-9 · Cited by 9
Metabolic activity via 18F-FDG PET/CT is predictive of microsatellite instability status in colorectal cancer
Jinling, S., Li, Z., Yang, L., Wei, M., Yang, Z., & Wang, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-09871-z · Cited by 9
Role of one-step nucleic acid amplification in colorectal cancer lymph node metastases detection
Crafa, F., Vanella, S., Catalano, O. A., Pomykala, K. L., & Baiamonte, M. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i30.4019 · Cited by 9
Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer
Goel, S., Negassa, A., Khot, A. A., Goyal, D., Guo, S., Nandikolla, A. G., Bakirhan, K., Polineni, R. D., Shah, U., Chaudhary, I., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.03.004 · Cited by 9
Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period
Jiao, X., Hay, J. W., Sadeghi, S., & Barzi, A. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000684 · Cited by 9
Cancers colorectaux avec mutation V600E de BRAF : où en sommes-nous ?
Lièvre, A., de la Fouchardière, C., Samalin, E., Benoist, S., Phelip, J., André, T., & Lledo, G. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.017 · Cited by 9
Self-citation
Treatment and Outcomes of Colorectal Cancer in Armenia: A Real-World Experience From a Developing Country
Bardakhchyan, S., Mkhitaryan, S., Zohrabyan, D., Safaryan, L., Avagyan, A., Harutyunyan, L., Arakelyan, J., Tamamyan, G., & Tananyan, A. (2020) · JCO Global Oncology · doi:10.1200/go.20.00251 · Cited by 9
Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice
Ascrizzi, S., Arillotta, G. M., Grillone, K., Caridà, G., Signorelli, S., Ali, A., Romeo, C., Tassone, P., & Tagliaferri, P. (2023) · Cancers · doi:10.3390/cancers15153930 · Cited by 8
Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer
Yang, J., Yu, C., Li, H., Peng, D., Zhou, Q., Yao, J., Lv, J., Fang, S., Shi, J., Wei, Y., et al. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1371 · Cited by 8
Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer
Tanakaya, K., Yamaguchi, T., Hirata, K., Yamada, M., Kumamoto, K., Akiyama, Y., Ishimaru, K., Okamoto, K., Kawasaki, Y., Komine, K., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02892-1 · Cited by 11
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP
de la Fouchardière, C., Zaanan, A., de Montfort, A., Cohen, R., Sourd, S. L., Tougeron, D., Soularue, É., Dubreuil, O., Williet, N., Samalin, E., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02169 · Cited by 10
Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice
Satkunam, N., Wei, X. S., Biagi, J. J., Nanji, S. A., & Booth, C. M. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0166 · Cited by 8
Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma
Diaz-Mercedes, S., Archilla, I., Camps, J., de Lacy, A., Gorostiaga, Í., Momblan, D. N. D. M., Ibarzábal, A., Maurel, J., Chic, N., Bombí, J. A., et al. (2019) · Applied Health Economics and Health Policy · doi:10.1007/s40258-019-00482-7 · Cited by 8
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence
Nugteren, S., den Uil, S. H., Diemen, P. M. D., Simons-Oosterhuis, Y., Lindenbergh-Kortleve, D. J., van Haaften, D. H., Stockmann, H. B. A. C., Sanders, J., Meijer, G. A., Fijneman, R. J. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16427-5 · Cited by 8
The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
Liao, L., Tang, J., Hong, Z., Wu, J., Li, Y., Kong, L.-H., Han, K., Hou, Z., Zhang, C., Zhou, C., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11821-w · Cited by 9
Nouvelles classifications moléculaires du cancer colorectal, du cancer du pancréas et du cancer de l’estomac : vers un traitement à la carte ?
Dreyer, C., Afchain, P., Trouilloud, I., & André, T. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.05.007 · Cited by 8
Self-citation
Is Adjuvant Chemotherapy Efficient in Colon Cancer with High Microsatellite Instability? A Look Towards the Future
Schiappacasse, G., & Schiappacasse, E. D. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2991 · Cited by 8
Diagnosed with a common cancer at an unusual age: causal attributions of survivors of adolescent and young adult colorectal cancer
Staal, D. P., Vlooswijk, C. C. P., Mols, F., Lidington, E. K., van der Graaf, W. T. A., Bijlsma, R. M., & Husson, O. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05502-0 · Cited by 8
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis
Alarid‐Escudero, F., Schrag, D., & Kuntz, K. M. (2021) · Value in Health · doi:10.1016/j.jval.2021.07.019 · Cited by 8
Adjuvant treatment of colon cancer with microsatellite instability – the state of the art
Oneda, E., & Zaniboni, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103537 · Cited by 8
New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy
Szpejewska, J. E., Yilmaz, M., Falkmer, S., Arendt‐Nielsen, L., & Mørch, C. D. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100543 · Cited by 8
Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer
Hestetun, K. E., Rosenlund, B., Stanisavljević, L., Dahl, O., & Myklebust, M. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.853545 · Cited by 8
Efficacy and safety of traditional plant-based medicines for preventing chronic oxaliplatin-induced peripheral neurotoxicity in patients with colorectal cancer: A systematic review and meta-analysis with core herb contribution
Han, J., Lai, H.-Z., Li, W., Liao, H., Xiao, C., Li, X., You, F., & Guo, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117735 · Cited by 9
Role of circulating free DNA in colorectal cancer
Matikas, A., Voutsina, A., Trypaki, M., & Georgoulias, V. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i12.810 · Cited by 9
Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
Yang, L., He, W., Yang, Q., Kong, P., Xie, Q., Jiang, C., Zhang, B., & Xia, L. P. (2017) · Oncotarget · doi:10.18632/oncotarget.21839 · Cited by 8
Adjuvant Chemotherapy for Colon Cancer
Hoehn, R. S., & Smith, J. J. (2019) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001328 · Cited by 8
Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy
Tam, E. L., Draksharam, P. L., Park, J. A., & Sidhu, G. S. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/4314797 · Cited by 8
Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy
He, J., Cheng, J., Guan, Q., Yan, H., Li, Y., Zhao, W., Guo, Z., & Wang, X. (2019) · Cancer Science · doi:10.1111/cas.14263 · Cited by 8
Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy
Chang, H., Tao, Y., Wu, J., Chen, C., Liu, S., Ye, W., & Gao, Y. (2020) · BMC Cancer · doi:10.1186/s12885-020-06988-x · Cited by 8
Therapeutic implications of B-RAF mutations in colorectal cancer
Lebrun, H., Turpin, A., & Zerbib, P. (2021) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2021.04.002 · Cited by 8
The impact of socioeconomic status on survival in stage III colon cancer patients: A retrospective cohort study using the SEER census‐tract dataset
Dhahri, A., Kaplan, J. L., Naqvi, S. M. H., Brownstein, N. C., Ntiri, S. O., Imanirad, I., Felder, S. I., Dineen, S. P., Sanchez, J., Dessureault, S., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4099 · Cited by 7
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer
Kusumoto, T., Sunami, E., Ota, M., Yoshida, K., Sakamoto, Y., Tomita, N., Maeda, A., Mochizuki, I., Okabe, M., Kunieda, K., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.015 · Cited by 8
The Definition of Cure in Colon Cancer
Pastorino, A., Liu, H., Pederson, L., Martelli, V., Iveson, T. J., de Gramont, A., Alberts, S. R., George, T. J., Yothers, G., Harkin, A., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3760 · Cited by 8
Self-citation
Multidimensional decoding of colorectal cancer heterogeneity: Artificial intelligence-enabled precision exploration of single-cell and spatial transcriptomics
Luan, W.-Y., Zhao, Q., Zhang, Z., Xu, Z.-X., Lin, S.-X., & Miao, Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i10.110661 · Cited by 9
Presentation, Molecular Characteristics, Treatment, and Outcomes of Colorectal Cancer in Patients Older than 80 Years Old
Voutsadakis, I. A. (2023) · Medicina · doi:10.3390/medicina59091574 · Cited by 7
An Updated Review on Molecular Biomarkers in Diagnosis and Therapy of Colorectal Cancer
Ravichandran, S. N., Kumar, M. M., Das, A., Banerjee, A., Prasad, S. V., Sun-Zhang, A., Zhang, H., Anbalagan, M., Sun, X., & Pathak, S. (2023) · Current Cancer Drug Targets · doi:10.2174/0115680096270555231113074003 · Cited by 7
The E3 ubiquitin ligase MAEA promotes macrophage phagocytosis and inhibits gastrointestinal cancer progression by mediating PARP1 ubiquitination and degradation
Feng, Y., Zou, X., Huang, J., Huang, Z., Kuang, G., & Jiang, Y. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.102796 · Cited by 6
Prognostic and therapeutic implications related to glycosylation profiles of cancer-associated fibroblasts in colorectal cancer: insights from single-cell and bulk transcriptomics
Chen, K., Huang, H., Hu, Z., Zhu, Y., Yao, Y., Wang, Y., Chen, J., Li, Y., Li, D., & Wei, P. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01675-1 · Cited by 6
Effectiveness of adjuvant FOLFOX vs 5FU / LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach
Lund, J. L., Webster‐Clark, M., Hinton, S. P., Shmuel, S., Stürmer‎, T., & Sanoff, H. K. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5148 · Cited by 7
Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Lengyel, C. G. (2021) · Current Drug Targets · doi:10.2174/1389450122666210325121322 · Cited by 7
Adjuvant chemotherapy is associated with improved overall survival in select patients with Stage II colon cancer: A National Cancer Database analysis
Grant, R., Khan, T. M., Gregory, S. N., Coakley, B. A., Hernandez, J. M., Davis, J. L., & Blakely, A. M. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26970 · Cited by 7
Opportunities on the horizon for the management of early colon cancer
Knapen, D. G., de Haan, J. J., Fehrmann, R. S. N., de Vries, E. G. E., & de Groot, D. J. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103918 · Cited by 7
Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein–Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery
Akimoto, E., Kuwata, T., Shitara, K., Kawazoe, A., Sakamoto, N., Ishii, G., Ochiai, A., & Kinoshita, T. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13266-0 · Cited by 7
Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection
Hassan, H., Chakrabarti, S., Zemla, T., Yin, J., Wookey, V., Prasai, K., Abdellatief, A., Katta, R. R., Tran, N. H., Jin, Z., et al. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.106994 · Cited by 7
A Prospective Long-Term Follow-Up Study: The Application of Circulating Tumor Cells Analysis to Guide Adjuvant Therapy in Stage II Colorectal Cancer
Yu, J., Bai, Y., Jin, L., Zhang, Z., & Yang, Y. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14168-x · Cited by 7
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
Wu, A., Anderson, H., Hughesman, C. B., Young, S. S., Lohrisch, C. A., Ross, C. J., & Carleton, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257745 · Cited by 7
Should rectal cancer located 10–15 cm from the anal verge be defined as colon cancer
Swets, M., Breugom, A. J., Gelderblom, H. A. J., & van de Velde, C. J. �. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw620 · Cited by 7
Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy
Mejri, N., Dridi, M., Labidi, S., Benna, H. E., Daoud, N., & Boussen, H. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1696-0 · Cited by 7
Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta‐analysis
Wang, J., Luo, L., Wang, D., Guo, B., Li, J., Zhu, Y., & Tang, D. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26312 · Cited by 8
Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer
Ubillos, L., Berriel, E., Mazal, D., Victoria, S., Barrios, E., Osinaga, E., & Berois, N. (2018) · Oncology Letters · doi:10.3892/ol.2018.8686 · Cited by 7
Noninferiority of three months versus six months of oxaliplatin‐based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?
Formica, V., Zaniboni, A., Loupakis, F., & Roselli, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31616 · Cited by 7
Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet‑embedded drug sensitivity test
Ochiai, T., Nishimura, K., Watanabe, T., Kitajima, M., Nakatani, A., Nagayasu, K., Sakuyama, N., Sato, T., Kishine, K., Abe, Y., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9805 · Cited by 7
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials
Zaanan, A., Shi, Q., Taı̈eb, J., Alberts, S. R., Meyers, J. P., Smyrk, T. C., Julié, C., Zawadi, A., Tabernero, J. M., Mini, E., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00237 · Cited by 7
Self-citation
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients
Margalit, O., Boursi, B., Rakez, M., André, T., Yothers, G., Wolmark, N., Haller, D. G., Schmoll, H., Shi, Q., Shacham‐Shmueli, E., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.02.001 · Cited by 8
Self-citation
Histomorphological and molecular genetic characterization of different intratumoral regions and matched metastatic lymph nodes of colorectal cancer with heterogenous mismatch repair protein expression
Zhang, J., Zhang, X., Wang, Q., Xu, Y., Yao, Q., Huang, D., Sheng, W., Zhu, X., Zhou, X., & Bai, Q. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04261-1 · Cited by 7
Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study
Heervä, E., Carpelan, A., Kurki, S. H., Sundström, J. T. T., Huhtinen, H., Rantala, A., Ålgars, A., Ristamäki, R., Carpén, O., & Minn, H. R. I. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1420230 · Cited by 7
Potential of SPHK1 as a prognostic marker and therapeutic target in colorectal cancer: insights from bioinformatics and experimental analysis
Miao, Y., Gan, J., Ni, Y.-J., Zhang, Z., Yu, L.-X., Quan, W., Zhang, Z., Wang, H., Han, S., Qu, F.-Y., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002506 · Cited by 6
Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis
Tang, M., Price, T. J., Shapiro, J. D., Gibbs, P., Haller, D. G., Arnold, D., Peeters, M., Segelov, E., Roy, A. C., Tebbutt, N. C., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1444481 · Cited by 6
Estimating Treatment Effect of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Using Bayesian Networks
Sieswerda, M. S., van Rossum, R., Bermejo, I., Geleijnse, G., Aben, K. K. H., van Erning, F. N., de Hingh, I. H. J. T., Lemmens, V. E. P. P., Dekker, A. L. A. J., & Verbeek, X. A. A. M. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00080 · Cited by 6
Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer
Kang, D., Huang, S., Liao, Y., Mi, S., Zhou, J., Yu, F., Huang, R., Lu, Z., Pan, Z.-Z., Ma, W., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05473-4 · Cited by 6
Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer
van de Weerd, S., Torang, A., van den Berg, I., Lammers, V., van den Bergh, S., Brouwer, N. P. M., Nagtegaal, I. D., Koopman, M., Vink, G. R., van der Baan, F. H., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35120 · Cited by 6
The prognostic impact of tumor mutations and tumor-infiltrating lymphocytes in patients with localized pMMR colorectal cancer – A systematic review and meta-analysis
Nielsen, A. T., Saqi, I. K., Justesen, T. F., Madsen, M. T., Gögenür, I., & Orhan, A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104714 · Cited by 6
Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
Blinman, P. L., Martin, A. J., Jefford, M., Goldstein, D., Boadle, D., Morris, M. F., Tebbutt, N. C., Aiken, C., Harkin, A., Segelov, E., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa107 · Cited by 7
Impact of high-risk features for stage II adenocarcinoma of the appendix
Akce, M., Zakka, K. M., Penley, M. J., Jiang, R., Khalil, L. E., Alese, O. B., Shaib, W. L., Wu, C. S.-Y., Behera, M., & El‐Rayes, B. F. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100329 · Cited by 6
Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study
Okamoto, K., Nozawa, H., Hongo, K., Iida, Y., Kawai, K., Sasaki, K., Murono, K., Kita, Y., Ishihara, Y., Takabayashi, N., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01932-w · Cited by 6
Potential evidence of peritoneal recurrence in Stage-II colon cancer from the control arm of CALGB9581
Dahdaleh, F. S., Sherman, S. K., Witmer, H. D. D., Dhiman, A., Rajeev, R., Poli, E. C., Johnston, F. M., & Turaga, K. K. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.01.017 · Cited by 6
Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
Cho, J. R., Lee, K., Oh, H., Kim, J. W., Kim, J., Kim, D., Kim, J. H., & Kang, S. (2022) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2022.102.5.271 · Cited by 6
WRN Is a Promising Synthetic Lethal Target for Cancers with Microsatellite Instability (MSI)
Chan, E. M., Foster, K. J., & Bass, A. J. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_17 · Cited by 6

Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
André, T., de Gramont, A., Chibaudel, B., Tijeras‐Raballand, A., Duval, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.5 · Cited by 3
Self-citation
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
Fléjou, J., André, T., Chibaudel, B., Scriva, A., Hickish, T., Tabernero, J. M., Laethem, J. V., Banzi, M. C., Maartense, E., Shani, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3524 · Cited by 23
Self-citation
Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
Taı̈eb, J., Zaanan, A., Malicot, K. L., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J. M., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 164
Self-citation
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
André, T., Boni, C., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Bonetti, A. V., Clingan, P. R., Bridgewater, J. A., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,276
Self-citation
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 285

See all

Authors: André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., Banzi, M., Maartense, E., Shmueli, E., Carlsson, G. U., Scheithauer, W., Papamichael, D., Möehler, M., Landolfi, S., Demetter, P., Colote, S., Tournigand, C., Louvet, C., Duval, A., Fléjou, J.-F., & de Gramont, A.
Affiliations: Inserm (FR)
Thierry André and Jean-François Fléjou, Hôpital St Antoine; Thierry André and Jean-François Fléjou, University Pierre et Marie Curie Paris VI; Thierry André, Benoist Chibaudel, Annemilaï Tijeras-Raballand, Soudhir Colote, and Aimery de Gramont, Groupe Coopérateur Multdisciplinaire en Ocologie (GERCOR) Oncology Multidisciplinary Group and GERCOR-Innovative Research Consortium; Christophe Louvet, Institut Mutualiste Montsouris; Alex Duval, L'Institut National de la Santé et de la Recherche Médicale UMRS...
ORCID: André, Thierry
Chibaudel, Benoist
Hickish, Tamas
Tabernero, Josep
Banzi, Maria
Shmueli, Einat
Papamichael, Demetris
Landolfi, Stefania
Demetter, Pieter
Tournigand, Christophe
Louvet, Christophe
Duval, Alex
Fléjou, Jean-François
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-12-10
Volume: 33
Issue: 35
Pages: 4176-4187
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2015.63.4238
OpenAlex: W1960485012
Cited by: 683
References: 32
Citations by year: 2026: 43 · 2025: 56 · 2024: 75 · 2023: 65 · 2022: 74 · 2021: 92 · 2020: 97 · 2019: 47 · 2018: 59 · 2017: 41 · 2016: 32
FWCI: 19.22
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: European Society for Medical Oncology
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: colon cancer, adjuvant chemotherapy, oxaliplatin, FOLFOX4, 5-fluorouracil, leucovorin, BRAF mutation, mismatch repair deficiency, overall survival, disease-free survival, prognostic factors, stage II colon cancer, stage III colon cancer, mosaic studies, long-term follow-up, microsatellite instability, mismatch repair proteins
MeSH terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Colonic Neoplasms, Female, Fluorouracil, Follow-Up Studies, Humans, Infusions, Intravenous, Injections, Intravenous, Male, Middle Aged, Mutation, Neoplasm Staging, Organoplatinum Compounds, Prognosis, Valine, Odds Ratio, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival, Glutamic Acid, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate, DNA Mismatch Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks